132 related articles for article (PubMed ID: 10722315)
1. Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C.
Kim WR; Poterucha JJ; Gross JB
Hepatology; 2000 Mar; 31(3):807-8. PubMed ID: 10722315
[No Abstract] [Full Text] [Related]
2. Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C.
Poynard T
Gut; 2003 Oct; 52(10):1532. PubMed ID: 12970155
[No Abstract] [Full Text] [Related]
3. Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C.
Lin WA; Tarn YH; Tang SL
Aliment Pharmacol Ther; 2006 Nov; 24(10):1483-93. PubMed ID: 17081165
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C.
Wong JB; Davis GL; Pauker SG
Am J Med; 2000 Apr; 108(5):366-73. PubMed ID: 10759092
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden.
Sennfält K; Reichard O; Hultkrantz R; Wong JB; Jonsson D
Scand J Gastroenterol; 2001 Aug; 36(8):870-6. PubMed ID: 11495084
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.
Buti M; Medina M; Casado MA; Wong JB; Fosbrook L; Esteban R
Aliment Pharmacol Ther; 2003 Mar; 17(5):687-94. PubMed ID: 12641518
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium.
Wong J; Nevens F
Acta Gastroenterol Belg; 2002; 65(2):110-11. PubMed ID: 12171045
[No Abstract] [Full Text] [Related]
8. Decisions, decisions, decisions.
Koretz RL
Gastroenterology; 2000 Jun; 118(6):1268-70. PubMed ID: 10833503
[No Abstract] [Full Text] [Related]
9. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Arguedas M
Pharmacoeconomics; 2004; 22(7):477-8; author reply 478-9. PubMed ID: 15137884
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.
Campos NG; Salomon JA; Servoss JC; Nunes DP; Samet JH; Freedberg KA; Goldie SJ
Am J Med; 2007 Mar; 120(3):272-9. PubMed ID: 17349451
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of chronic hepatitis C treatment by interferon-ribavirin combination therapy in Belgium.
Delwaide J
Acta Gastroenterol Belg; 2002; 65(4):233-6. PubMed ID: 12619432
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.
Younossi ZM; Singer ME; McHutchison JG; Shermock KM
Hepatology; 1999 Nov; 30(5):1318-24. PubMed ID: 10534357
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.
Grieve R; Roberts J; Wright M; Sweeting M; DeAngelis D; Rosenberg W; Bassendine M; Main J; Thomas H
Gut; 2006 Sep; 55(9):1332-8. PubMed ID: 15994216
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Wong JB; Poynard T; Ling MH; Albrecht JK; Pauker SG
Am J Gastroenterol; 2000 Jun; 95(6):1524-30. PubMed ID: 10894590
[TBL] [Abstract][Full Text] [Related]
15. [Does combination therapy of chronic viral hepatitis C with interferon-alpha and ribavirin approach financial limits?].
Steimann RU; Bode JC
Versicherungsmedizin; 2000 Mar; 52(1):24-7. PubMed ID: 10718088
[TBL] [Abstract][Full Text] [Related]
16. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C.
Gerkens S; Nechelput M; Annemans L; Peraux B; Mouchart M; Beguin C; Horsmans Y
J Viral Hepat; 2007 Aug; 14(8):523-36. PubMed ID: 17650286
[TBL] [Abstract][Full Text] [Related]
17. Making it happen: managed care considerations in vanquishing hepatitis C.
McHutchison JG; Bacon BR; Owens GS
Am J Manag Care; 2007 Dec; 13 Suppl 12():S327-36; quiz S337-40. PubMed ID: 18095781
[TBL] [Abstract][Full Text] [Related]
18. r-Interferon alfa-2b/ribavirin combined therapy followed by low-dose r-interferon alfa-2b in chronic hepatitis C interferon nonresponders.
Perasso A; Testino G; Ansaldi F; Venturino V; Icardi GC
Hepatology; 1999 Jan; 29(1):297-8. PubMed ID: 9935339
[No Abstract] [Full Text] [Related]
19. [Budget impact analysis of the treatment of chronic hepatitis C in a hospital].
Casado Gómez MA; Alvarez-Rubio L; Miró Manero S; Mariño Hernández EL; Buti Ferret M
Farm Hosp; 2006; 30(5):291-9. PubMed ID: 17166063
[TBL] [Abstract][Full Text] [Related]
20. What is (cost) effective in patients with chronic hepatitis C virus infection?
Zeuzem S
Eur J Gastroenterol Hepatol; 2001 May; 13(5):473-6. PubMed ID: 11396523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
